
This episode features Dave, the CEO of Eli Lilly, discussing the company's leadership in the GLP-1 drug market, the rise in market capitalization, and the development of a new oral medication.
Dave highlights Eli Lilly's significant growth, noting an 860% increase in market capitalization since he took over as CEO. He emphasizes the importance of advancing both external and internal science in the pharmaceutical industry.
The conversation touches on the effectiveness of Eli Lilly's experimental pill, which reportedly works as well as the traditional injected GLP-1 drugs, offering a needle-free option for patients.
Listeners gain insights into the pharmaceutical landscape and Eli Lilly's role in shaping the future of diabetes treatment.
Dave, CEO of Eli Lilly, discusses GLP-1 drugs and the company's growth in the pharmaceutical market.

Eli Liy coming to save us here.🚨 All-In Summit Speaker Announcement: Dave Ricks
No need for needles. Eli Liy says it has a pill.🚨 All-In Summit Speaker Announcement: Dave Ricks